TL;DR:
- ArisGlobal has launched LifeSphere NavaX, a cutting-edge cognitive computing engine for R&D IT digitization in life sciences.
- LifeSphere NavaX introduces advanced technologies, including Large Language Models (LLM) and Generative AI (Gen AI).
- It builds upon the industry-leading LifeSphere R&D compliance platform, offering enhanced efficiency and innovation.
- Key features include Proactive Signal Detection, Generative AI, and Large Language Models.
- The survey reveals a growing interest in Gen AI adoption, with 49% of Life Sciences organizations planning to deploy it in the next year.
- LifeSphere NavaX addresses challenges such as rising case volumes, regulatory complexity, and the need for data analytics.
- ArisGlobal aims to empower pharmaceutical, biotech, and health authorities with advanced technology.
Main AI News:
In a dynamic move aimed at accelerating R&D IT Digitization in the Life Sciences sector, ArisGlobal, a renowned leader in Life Sciences technology and the mastermind behind LifeSphere®, has introduced the cutting-edge LifeSphere NavaX. This remarkable innovation harnesses advanced technologies, such as Large Language Models (LLM) and Generative AI (Gen AI), to revolutionize the landscape.
LifeSphere stands tall as the premier R&D compliance platform within the industry. Back in 2018, ArisGlobal introduced LifeSphere MultiVigilance (LSMV), a platform designed for the intake of individual case safety reports (ICSR). Powered by the inaugural LifeSphere Nava (v1), it ushered in the latest in robotic process automation and cognitive computing technologies. These included natural language processing (NLP) and machine learning (ML), effectively reshaping pharmacovigilance (PV) activities.
Today, LifeSphere NavaX takes center stage, armed with next-generation technologies poised to deliver comprehensive efficiency gains across the end-to-end PV and regulatory processes. Organizations adopting LifeSphere NavaX will gain access to ArisGlobal’s latest innovations, which encompass:
• Proactive Signal Detection, leveraging Real-World Data
• Generative AI (Gen AI)
• Large Language Models (LLM) features and functionality
According to a survey conducted for the Gartner 2024 CIO Agenda, a staggering 49% of Life Sciences organizations express a desire to deploy Gen AI within the next 12 months. Furthermore, 15% plan deployment within 12-24 months, with only 8% having already implemented this technology. This growing appetite for smart process automation reflects the mounting pressure on Life Sciences companies, as well as their PV and Regulatory operations, to enhance agility and efficiency while maintaining the highest standards of patient safety, quality, and compliance.
Aman Wasan, CEO of ArisGlobal, expressed the company’s vision, stating, “Our mission is to revolutionize the R&D IT ecosystem with cutting-edge technology. NavaX will empower global pharmaceutical, biotech, and health authorities to unlock tremendous value through the adoption of advanced technology. With over 30 years of experience in the Life Sciences industry, the ArisGlobal team is dedicated to partnering closely with each customer to unlock extraordinary benefits with NavaX.“
Ann-Marie Orange, CIO & Global Head of R&D at ArisGlobal, highlighted the monumental challenges faced by companies, including the surge in case volumes, the need to enhance drug safety and efficacy, rising R&D costs, regulatory complexity, and the demand to harness big data and analytics. She noted that these challenges are compounded by inefficient legacy IT systems, workflows, processes, and resource constraints. Orange emphasized, “Our LifeSphere platform encapsulates decades of R&D and compliance expertise, making it accessible to our clients. LifeSphere NavaX builds upon our proven platform, granting the Life Sciences industry access to digital innovations that are propelling the world forward.”
Key Highlights of NavaX Technology:
- Scalability and Customizability: NavaX empowers PV and Regulatory teams to maintain control and set their own pace, aligning with their objectives, goals, and timelines.
- Seamless Integration: NavaX seamlessly integrates with third-party systems, ensuring a smooth transition towards a more intelligent and automated future.
- Collaboration and Compliance: NavaX thrives on continuous input from pharmaceutical and regulatory partners, adhering to the highest standards and robust governance frameworks.
Currently, over 500 global pharmaceutical and biotech companies, including 90% of the Top 10 pharma brands, leverage LifeSphere—a testament to ArisGlobal’s open R&D and compliance platform’s transformative impact. Existing LifeSphere platform customers have already achieved remarkable process efficiency gains and cost savings. With NavaX driving next-generation digital process innovation, operational efficiency will soar, insights will arrive faster, and compliance will be further assured.
Conclusion:
ArisGlobal’s launch of LifeSphere NavaX signifies a significant step towards accelerating R&D IT Digitization in the Life Sciences sector. With a strong demand for advanced technologies like Gen AI and a track record of empowering industry leaders, ArisGlobal is well-positioned to shape the future of R&D in Life Sciences. This innovation promises to boost efficiency and compliance while meeting the growing needs of pharmaceutical, biotech, and health authorities.
